211At-ch81C6

211At-ch81C6 is a targeted alpha-particle radioimmunotherapy consisting of the chimeric monoclonal antibody ch81C6 labeled with the alpha-emitting radioisotope Astatine-211 (211At). Developed primarily by researchers at Duke University, this agent is designed to treat malignant gliomas, particularly glioblastoma multiforme. The antibody component, ch81C6, specifically targets tenascin-C, a hexabrachion glycoprotein that is highly expressed in the extracellular matrix of most high-grade gliomas but virtually absent in normal adult brain tissue. By delivering 211At directly to the tumor site—often via administration into the surgically created resection cavity—the drug utilizes high linear energy transfer (LET) alpha particles to induce lethal double-strand DNA breaks in nearby malignant cells. This localized approach minimizes systemic toxicity and radiation exposure to healthy brain tissue due to the short path length (55–80 μm) of the alpha particles.

Other names

Astatine-211-labeled chimeric monoclonal antibody 81C6Astatine211-labeled chimeric monoclonal antibody 81C6Astatine 211-labeled chimeric monoclonal antibody 81C6[211At]ch81C6211At-labeled ch81C6